# Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response

> **NCT03767452** · PHASE4 · UNKNOWN · sponsor: **Manhattan Medical Research Practice, PLLC** · enrollment: 20 (estimated)

## Conditions studied

- Peyronie's Disease

## Interventions

- **DRUG:** Xiaflex® 0.58 mg

## Key facts

- **NCT ID:** NCT03767452
- **Lead sponsor:** Manhattan Medical Research Practice, PLLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-04
- **Primary completion:** 2019-12
- **Final completion:** 2020-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2018-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03767452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03767452, "Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03767452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*